Generation of a conditionally neo(r)-containing retroviral producer cell line: effects of neo(r) on retroviral titer and transgene expression

Autor: EG Krecko, Fabio Candotti, Oliver Wildner, WJ Ramsey, R M Blaese, KG Xanthopoulos

Publikováno v: Gene therapy. 5(5)

We have developed a method for generating high-titer retroviral producer cell lines conditionally containing a neomycin resistance gene (neo(r)) based on the Cre/loxP system. For this, a bicistronic retroviral splicing vector carrying the green fluor

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9c8de93965a98887a7eeb5fb273ba87f
https://pubmed.ncbi.nlm.nih.gov/9797874

Fetal and adult localization of C/EBP: evidence for combinatorial action of transcription factors in cell-specific gene expression

Autor: CF Kuo, Jr Je Darnell, KG Xanthopoulos

Publikováno v: Development (Cambridge, England). 109(2)

C/EBP is a positive-acting transcription factor important for hepatocyte-specific expression present not only in hepatocytes but also a limited number of other cell types in adult mice. By Northern blot analysis and in situ hybridization experiments

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::20514d847805358fdac6c61e6baa1154
https://pubmed.ncbi.nlm.nih.gov/2401206

US immigration order strikes against biotech.

Autor: Levin JM; Ovid Therapeutics, New York, New York, USA., Holtzman SH; Decibel Therapeutics, Cambridge, Massachusetts, USA., Maraganore J; Alnylam Pharmaceuticals, Cambridge, Massachusetts, USA., Hastings PJ; OncoMed Pharmaceuticals, Redwood City, California, USA., Cohen R; Acorda Therapeutics, Inc., Ardsley, New York, USA., Dahiyat B; Xencor, Monrovia, California, USA., Adams J; Clal Biotechnology Industries (CBI), Cambridge, Massachusetts, USA., Adams C; Cydan Development Inc., Cambridge, Massachusetts, USA., Ahrens B; Canaan Partners, Menlo Park, California, USA., Albers J; Blueprint Medicines, Cambridge, Massachusetts, USA., Aspinall MG; Health Catalysts, Tucson, Arizona, USA., Audia JE; Constellation Pharmaceuticals, Inc., Cambridge, Massachusetts, USA., Babler M; Principia Biopharma, South San Francisco, California, USA., Barrett P; Atlas Venture, Cambridge, Massachusetts, USA., Barry Z; ZappRx, Boston, Massachusetts, USA., Bermingham N; Intellia Therapeutics, Cambridge, Massachusetts, USA., Bloch S; Canaan Partners, Westport, Connecticut, USA., Blum RI; Cytokinetics, Inc., South San Francisco, California, USA., Bolno PB; Wave Life Sciences, Cambridge, Massachusetts, USA., Bonney MW; Alnylam Pharmaceuticals, Cambridge, Massachusetts, USA., Booth B; Atlas Venture, Cambridge, Massachusetts, USA., Bradbury DM; Amylin Pharmaceuticals, San Diego, California, USA., Brauer SK; Salus Discovery LLC, San Diego, California, USA., Byers B; Biotech Venture Capitalist since 1978, Menlo Park, California, USA., Cagnoni PJ; Tizona Therapeutics, Inc., South San Francisco, California, USA., Cali BM; Ironwood Pharmaceuticals, Cambridge, Massachusetts, USA., Ciechanover I; Atara Bio, South San Francisco, California, USA., Clark C; Genocea Biosciences, Inc., Cambridge, Massachusetts, USA., Clayman MD; Flexion Therapeutics, Burlington, Massachusetts, USA., Cleland JL; Graybug Vision, Redwood City, California, USA., Cobb P; Decibel Therapeutics, Cambridge, Massachusetts, USA., Cooper R; Albireo Pharma Inc., Boston, Massachusetts, USA., Currie MG; Ironwood Pharmaceuticals, Cambridge, Massachusetts, USA., Diekman J; 5AM Ventures, Boston, Massachusetts, USA., Dobmeier EL; Seattle Genetics, Bothell, Washington, USA., Doerfler D; MaxCyte, Inc., Gaithersburg, Maryland, USA., Donley EL; NeuroPoint Dx, Madison, Wisconsin, USA., Dunsire D; Southern Cross Biotech Consulting, Waltham, Massachusetts, USA., During M; Ovid Therapeutics, New York, New York, USA., Eckstein JW; SR One, Conshohocken, Pennsylvania, USA., Elenko E; PureTech Health, Boston, Massachusetts, USA., Exter NA; Third Rock Ventures, Boston, Massachusetts, USA., Fleming JJ; Q-State Biosciences, Cambridge, Massachusetts, USA., Flesher GJ; OticPharma Inc., Irvine, California, USA., Formela JF; Atlas Venture, Cambridge, Massachusetts, USA., Forrester R; Verastem Inc., Needham, Massachusetts, USA., Francois C; Apellis Pharmaceuticals, Crestwood, Kentucky, USA., Franklin H; Blaze Bioscience Inc., Seattle, Washington, USA., Freeman MW; 5AM Ventures, Boston, Massachusetts, USA., Furst H; Deerfield Management, New York, New York, USA., Gage LP; Tetraphase, Watertown, Massachusetts, USA., Galakatos N; Clarus, Cambridge, Massachusetts, USA., Gallagher BM; SR One, Ltd., Cambridge, Massachusetts, USA., Geraghty JA; Juniper Pharmaceuticals, Boston, Massachusetts, USA., Gill S; Evelo Biosciences, Cambridge, Massachusetts, USA., Goeddel DV; The Column Group, San Francisco, California, USA., Goldsmith MA; Revolution Medicines, Inc., Redwood City, California, USA., Gowen M; Trevena Inc., King of Prussia, Pennsylvania, USA., Goyal V; SR One, Ltd., Cambridge, Massachusetts, USA., Graney T; Ironwood Pharmaceuticals, Cambridge, Massachusetts, USA., Grayzel D; Atlas Venture, Cambridge, Massachusetts, USA., Greene B; Alnylam Pharmaceuticals, Cambridge, Massachusetts, USA., Grint P; Regulus Therapeutics, San Diego, California, USA., Gutierrez-Ramos JC; Synlogic, Cambridge, Massachusetts, USA., Haney B; Dragonfly Therapeutics, Inc., Cambridge, Massachusetts, USA., Ha-Ngoc T; KEW, Inc., Cambridge, Massachusetts, USA., Harris T; SV Life Sciences, Boston, Massachusetts, USA., Hasnain F; FSG Biotech, San Diego, California, USA., Hata YS; IDEAYA Biosciences, South San Francisco, California, USA., Hecht P; Ironwood Pharmaceuticals, Cambridge, Massachusetts, USA., Henshaw L; Deerfield Management, New York, New York, USA., Heyman R; Metacrine, Inc., San Diego, California, USA., Hoppenot H; Incyte, Wilmington, Delaware, USA., Horvitz HR; Massachusetts Institute of Technology, Cambridge, Massachusetts, USA., Hughes TE; Zafgen, Inc., Boston, Massachusetts, USA., Hutton WS; Canaan Partners, Menlo Park, California, USA., Isaacs ST; Aduro Biotech, Berkley, California, USA., Jenkins A; Dimension Therapeutics, Cambridge, Massachusetts, USA., Jonker J; NGM Biopharmaceuticals, Inc., South San Francisco, California, USA., Kaplan J; Deerfield Management, New York, New York, USA., Karsen P; Intellia Therapeutics, Cambridge, Massachusetts, USA., Keiper J; Nimbus Therapeutics, Cambridge, Massachusetts, USA., Kim J; Deerfield Management, New York, New York, USA., Kindler J; Centrexion Therapeutics Inc., Boston, Massachusetts, USA., King R; GlycoMimetics, Inc., Rockville, Maryland, USA., King V; Luc Therapeutics, Inc., Cambridge, Massachusetts, USA., Kjellson N; Canaan Partners, Menlo Park, California, USA., Koenig S; MacroGenics, Inc., Rockville, Maryland, USA., Koenig G; Quartet Medicine, Cambridge, Massachusetts, USA., Kolchinsky P; RA Capital Management, LLC, Boston, Massachusetts, USA., Laikind P; ViaCyte, Inc., San Diego, California, USA., Langer RB; Massachusetts Institute of Technology, Cambridge, Massachusetts, USA., Lee JJ; Decibel Therapeutics, Cambridge, Massachusetts, USA., Leff JS; Deerfield Management, New York, New York, USA., Leicher BA; Momenta Pharmaceuticals, Inc., Cambridge, Massachusetts, USA., Leschly N; Bluebird Bio, Cambridge, Massachusetts, USA., Levin A; RA Capital Management, LLC, Boston, Massachusetts, USA., Levin M; Third Rock Ventures, Boston, Massachusetts, USA., Levine AJ; Institute for Advanced Study, Princeton, New Jersey, USA., Levy A; Chrono Therapeutics, Hayward, California, USA., Liu DR; Editas Medicine, Cambridge, Massachusetts, USA., Lodish HF; Whitehead Institute MIT, Cambridge, Massachusetts, USA., Lopatin U; Assembly Biosciences, Carmel, Indiana, USA., Love TW; Global Blood Therapeutics, South San Francisco, California, USA., Macdonald G; Tetraphase, Watertown, Massachusetts, USA., Maderis GJ; Antiva Biosciences, Inc., South San Francisco, California, USA., Mahadevia A; Spero Therapeutics, Cambridge, Massachusetts, USA., Mahanthappa NK; Scholar Rock, Cambridge, Massachusetts, USA., Martin JF; Dauntless Pharmaceuticals, Inc., San Diego, California, USA., Martin A; Realm Therapeutics, Malvern, Pennsylvania, USA., Martucci WE; Akili Interactive, Boston, Massachusetts, USA., McArthur JG; Imara, Cambridge, Massachusetts, USA., McCann CM; Pear Therapeutics, Boston, Massachusetts, USA., McCarthy SA; CytomX, South San Francisco, California, USA., McDonough CG; Sobi, Waltham, Massachusetts, USA., Mendlein J; aTyr Pharma, San Diego, California, USA., Miller L; Macrolide Pharmaceuticals, Watertown, Massachusetts, USA., Miralles D; Adaptive Biotechnologies, Seattle, Washington, USA., Moch KI; Cognition Therapeutics, Inc., Pittsburgh, Pennsylvania, USA., More B; Alta Partners, San Francisco, California, USA., Myers AG; Harvard University, Cambridge, Massachusetts, USA., Narachi MA; Orexigen Therapeutics, La Jolla, California, USA., Nashat A; Polaris Partners, Boston, Massachusetts, USA., Nelson W; Boston Biotech Forum, Cambridge, Massachusetts, USA., Newell WJ; Sutro Biopharma, Inc., South San Francisco, California, USA., Olle B; Vedanta Biosciences, Inc., Cambridge, Massachusetts, USA., Osborn JE; Egalet, Wayne, Pennsylvania, USA., Owens JC; Millendo Therapeutics, Inc., Ann Arbor, Michigan, USA., Pande A; Verity BioConsulting, San Diego, California, USA., Papadopoulos S; Biogen Inc., Exelixis Inc. &Regulus Therapeutics Inc., Great Neck, New York, USA., Parker HS; Parker BioConsulting, Seattle, Washington, USA., Parmar KM; 5AM Ventures, Boston, Massachusetts, USA., Patterson MR; Audentes Therapeutics, Inc., San Francisco, California, USA., Paul SM; Voyager Therapeutics, Inc., Cambridge, Massachusetts, USA., Perez R; Life Science Cares, Boston, Massachusetts, USA., Perry M; BVF Partners, LP, San Francisco, California, USA., Pfeffer CG; Third Rock Ventures, Boston, Massachusetts, USA., Powell M; Sofinnova Ventures, Menlo Park, California, USA., Pruzanski M; Intercept Pharma, New York, New York, USA., Purcell DJ; Aisling Capital, New York, New York, USA., Rakhit A; Ovid Therapeutics, New York, New York, USA., Ramamoorthi K; Encoded Genomics, South San Francisco, California, USA., Rastetter W; Neurocrine Biosciences Inc., San Diego, California, USA., Rawcliffe AA; Adaptimmune, Philadelphia, Pennsylvania, USA., Reid LE; Warp Drive Bio, Cambridge, Massachusetts, USA., Renaud RC; RaNa Therapeutics, Cambridge, Massachusetts, USA., Rhodes JP; Atlas Venture, Cambridge, Massachusetts, USA., Rieflin WJ; NGM Biopharmaceuticals, Inc., South San Francisco, California, USA., Robins C; Adaptive Biotechnologies, Seattle, Washington, USA., Rocklage SM; 5AM Ventures, San Francisco, California, USA., Rosenblatt M; Flagship Pioneering, Cambridge, Massachusetts, USA., Rosin JG; Ironwood Pharmaceuticals, Cambridge, Massachusetts, USA., Rutter WJ; Synergenics, LLC, San Francisco, California, USA., Saha S; Delinia, Cambridge, Massachusetts, USA., Samuels C; Venrock, Palo Alto, California, USA., Sato VL; Harvard Business School, Cambridge, Massachusetts, USA., Scangos G; Vir Bio, San Francisco, California, USA., Scarlett JA; Geron Corporation, Menlo Park, California, USA., Schenkein D; Agios, Cambridge, Massachusetts, USA., Schreiber SL; Broad Institute, Cambridge, Massachusetts, USA., Schwab A; 5AM Ventures, San Francisco, California, USA., Sekhri P; Lycera Corporation, New York, New York, USA., Shah R; RA Capital Management, LLC, Boston, Massachusetts, USA., Shenk T; Lewis Thomas Laboratory, Princeton, New Jersey, USA., Siegall CB; Seattle Genetics, Bothell, Washington, USA., Simon NJ; Clarus Ventures LLC, South San Francisco, California, USA., Simonian N; Syros Pharmaceuticals, Cambridge, Massachusetts, USA., Stein J; Cidara Therapeutics, San Diego, California, USA., Su M; Decibel Therapeutics, Cambridge, Massachusetts, USA., Szela MT; Novelion Therapeutics, Vancouver, British Columbia, USA., Taglietti M; SCYNEXIS, Inc., Jersey City, New Jersey, USA., Tandon N; EpiBone, Inc., New York, New York, USA., Termeer H; Genzyme Corporation (former CEO), Cambridge, Massachusetts, USA., Thornberry NA; Kallyope, New York, New York, USA., Tolar M; Alzheon, Framingham, Massachusetts, USA., Ulevitch R; 5AM Ventures, La Jolla, California, USA., Vaishnaw AK; Alnylam Pharmaceuticals, Cambridge, Massachusetts, USA., VanLent A; AMV Advisors, Princeton, New Jersey, USA., Varsavsky M; Prelude Fertility, Inc., Atlanta, Georgia, USA., Vlasuk GP; Navitor Pharmaceuticals, Inc., Cambridge, Massachusetts, USA., Vounatsos M; Biogen, Cambridge, Massachusetts, USA., Waksal SG; MeiraGTx, New York, New York, USA., Warma N; Opexa Therapeutics, Inc., The Woodlands, Texas, USA., Watts RJ; Denali Therapeutics Inc., South San Francisco, California, USA., Werber Y; Ovid Therapeutics, New York, New York, USA., Westphal C; Flex Pharma, Boston, Massachusetts, USA., Wierenga W; Crinetics Pharmaceuticals, San Diego, California, USA., Williams DE; Codiak BioSciences, Cambridge, Massachusetts, USA., Williams LR; Five Prime Therapeutics, Inc., South San Francisco, California, USA., Xanthopoulos KG; Cerus, La Jolla, California, USA., Zohar D; PureTech Health, Boston, Massachusetts, USA., Zweifach SS; Nuvelution Pharmaceuticals, Inc., South San Francisco, California, USA.

Publikováno v: Nature biotechnology [Nat Biotechnol] 2017 Mar 07; Vol. 35 (3), pp. 204-206.

Suppression of C/EBPalpha expression in periportal hepatoblasts may stimulate biliary cell differentiation through increased Hnf6 and Hnf1b expression.

Autor: Yamasaki H; Department of Biology, Faculty of Science, Shizuoka University, 836 Oya, Surugaku, Shizuoka City, Shizuoka 422-8529, Japan., Sada A, Iwata T, Niwa T, Tomizawa M, Xanthopoulos KG, Koike T, Shiojiri N

Publikováno v: Development (Cambridge, England) [Development] 2006 Nov; Vol. 133 (21), pp. 4233-43. Date of Electronic Publication: 2006 Oct 04.

Development of improved Sindbis virus-based DNA expression vector.

Autor: Yamanaka R; Clinical Gene Therapy Branch, National Human Genome Research Institute, National Institutes of Health, Bethesda, Maryland, USA. ryaman@bri.niigata-ac.jp, Xanthopoulos KG

Publikováno v: DNA and cell biology [DNA Cell Biol] 2004 Feb; Vol. 23 (2), pp. 75-80.